Coordinated cellular responses track cognitive outcomes in Alzheimer's disease
Related Experiment Video
Updated: Nov 9, 2026

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
Abstract:
Individuals with comparable Alzheimer's disease (AD) pathology can differ markedly in cognition, but the molecular nature of this heterogeneity remains unclear. Here we profiled paired gene expression and chromatin accessibility in 1.42 million nuclei from three cortical regions of 247 donors. A pathology-supervised transcriptomic score, supported by paired chromatin measurements, resolved cellular disease state differences within samples and between individuals. After adjustment for measured pathology, cellular responses were concordant across major cell classes and cortical regions. Higher pathology-adjusted responses were associated with lower relative abundance of vulnerable excitatory and somatostatin-expressing inhibitory neurons and poorer cognitive outcomes. Pathology-associated, pathology-adjusted, and within-sample cellular-state differences converged on overlapping molecular programs. Unsupervised analysis identified reproducible donor-associated transcriptional programs, including a proteostasis and cellular-stress program associated with higher pathology-adjusted responses, contrasting a lipid-metabolic and biosynthetic program showing the opposite relationship across regions and cohorts. Together, these findings identify a coordinated molecular phenotype associated with differences in neuronal composition and cognition among individuals with comparable measured neuropathology.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Cognitive Development During Adulthood
Dementia l: Introduction
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
